Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
Colorectal cancer is the third most frequent cancer worldwide. Overall survival rates have improved greatly over the last few years due, at least in part, to the addition of targeted therapies to standard of care chemotherapy. Angiogenesis plays an important role in colorectal cancer, and therapies...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-05-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758834016635888 |
| _version_ | 1811307803986362368 |
|---|---|
| author | Helena Verdaguer Josep Tabernero Teresa Macarulla |
| author_facet | Helena Verdaguer Josep Tabernero Teresa Macarulla |
| author_sort | Helena Verdaguer |
| collection | DOAJ |
| description | Colorectal cancer is the third most frequent cancer worldwide. Overall survival rates have improved greatly over the last few years due, at least in part, to the addition of targeted therapies to standard of care chemotherapy. Angiogenesis plays an important role in colorectal cancer, and therapies directed against the vascular endothelial growth factor (VEGF) axis have contributed significantly to improving the outcome of patients with metastatic colorectal cancer. Over the past few years, several new targeted antiangiogenic agents have been approved for this patient population, confirming the value of inhibiting tumour angiogenesis. The most recent among them is ramucirumab, a fully humanized monoclonal antibody that targets the extracellular domain of VEGF receptor 2. It has proven valuable in multiple tumour types including colorectal cancer. Several phase I and II clinical trials showed a favourable toxicity profile and promising clinical antitumour efficacy in colorectal cancer patients. In the phase III RAISE clinical trial, the addition of ramucirumab to FOLFIRI-based chemotherapy resulted in an improvement of overall survival in patients with metastatic colorectal cancer who had been previously treated with bevacizumab, oxaliplatin and a fluoropyrimidine. On the basis of these results, ramucirumab was approved by the US Food and Drug Administration for this setting. We present an overview of the key preclinical and clinical studies in the development of ramucirumab in the context of metastatic colorectal cancer. |
| first_indexed | 2024-04-13T09:10:50Z |
| format | Article |
| id | doaj.art-1dde713f03064a1f92610b162f98eb33 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-13T09:10:50Z |
| publishDate | 2016-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-1dde713f03064a1f92610b162f98eb332022-12-22T02:52:53ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592016-05-01810.1177/1758834016635888Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapyHelena VerdaguerJosep TaberneroTeresa MacarullaColorectal cancer is the third most frequent cancer worldwide. Overall survival rates have improved greatly over the last few years due, at least in part, to the addition of targeted therapies to standard of care chemotherapy. Angiogenesis plays an important role in colorectal cancer, and therapies directed against the vascular endothelial growth factor (VEGF) axis have contributed significantly to improving the outcome of patients with metastatic colorectal cancer. Over the past few years, several new targeted antiangiogenic agents have been approved for this patient population, confirming the value of inhibiting tumour angiogenesis. The most recent among them is ramucirumab, a fully humanized monoclonal antibody that targets the extracellular domain of VEGF receptor 2. It has proven valuable in multiple tumour types including colorectal cancer. Several phase I and II clinical trials showed a favourable toxicity profile and promising clinical antitumour efficacy in colorectal cancer patients. In the phase III RAISE clinical trial, the addition of ramucirumab to FOLFIRI-based chemotherapy resulted in an improvement of overall survival in patients with metastatic colorectal cancer who had been previously treated with bevacizumab, oxaliplatin and a fluoropyrimidine. On the basis of these results, ramucirumab was approved by the US Food and Drug Administration for this setting. We present an overview of the key preclinical and clinical studies in the development of ramucirumab in the context of metastatic colorectal cancer.https://doi.org/10.1177/1758834016635888 |
| spellingShingle | Helena Verdaguer Josep Tabernero Teresa Macarulla Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy Therapeutic Advances in Medical Oncology |
| title | Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy |
| title_full | Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy |
| title_fullStr | Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy |
| title_full_unstemmed | Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy |
| title_short | Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy |
| title_sort | ramucirumab in metastatic colorectal cancer evidence to date and place in therapy |
| url | https://doi.org/10.1177/1758834016635888 |
| work_keys_str_mv | AT helenaverdaguer ramucirumabinmetastaticcolorectalcancerevidencetodateandplaceintherapy AT joseptabernero ramucirumabinmetastaticcolorectalcancerevidencetodateandplaceintherapy AT teresamacarulla ramucirumabinmetastaticcolorectalcancerevidencetodateandplaceintherapy |